论文部分内容阅读
目的研究奥沙利铂联合替吉奥在胃癌化疗中的临床表现及效果。方法 46例胃癌患者,分为研究组和对照组,各23例。研究组使用奥沙利铂联合替吉奥,对照组使用紫杉醇+顺铂+5-氟尿嘧啶(5-Fu),对比两组胃癌患者生存率以及两组患者的临床反应。结果研究组总缓解率为82.61%,生存率为82.61%,均优于对照组的60.86%、60.86%,差异均具有统计学意义(P<0.05)。结论奥沙利铂联合替吉奥能够优化患者化疗期的生活质量,削弱毒副作用影响,有效提高胃癌患者的生存率,其临床应用价值及影响利好作用显著。
Objective To study the clinical manifestations and effects of oxaliplatin combined with tiagacid in gastric cancer chemotherapy. Methods 46 cases of gastric cancer patients were divided into study group and control group, 23 cases in each. The study group used oxaliplatin combined with tiagre, while the control group used paclitaxel + cisplatin + 5-fluorouracil (5-Fu) to compare the survival rate of two groups of patients with gastric cancer and the clinical response of the two groups. Results The total remission rate was 82.61% in the study group and the survival rate was 82.61%, both of which were better than 60.86% and 60.86% of the control group, respectively. The differences were statistically significant (P <0.05). Conclusion Combined use of oxaliplatin and tiagio can improve the quality of life of patients during chemotherapy, weaken the influence of toxic and side effects and effectively improve the survival rate of patients with gastric cancer. The clinical value and influence of oxaliplatin and tigiao are significant.